GlassScriptPhysician profile
Faisal A Khan
NPI 1477564748
$206,703.48
in general payments reported to CMS, 2019-2025
39 companies · $43K in 2025
The $43K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,578 · 2020: $12K · 2021: $24K · 2022: $23K · 2023: $45K · 2024: $52K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $126K · Travel and Lodging: $11K · Food and Beverage: $3,225 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $126,401.14 |
| Travel and Lodging | $11,210.21 |
| Food and Beverage | $3,224.54 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $118,895.67 | 2019-2025 | Monarch Platform |
| Medical Device Business Services, INC. | $55,186.33 | 2023-2025 | Monarch Platform, Monarch |
| Cook Incorporated | $10,965.00 | 2023-2025 | |
| Ethicon Endo-Surgery INC. | $10,400.00 | 2022-2023 | Monarch |
| Astrazeneca Pharmaceuticals LP | $5,247.67 | 2019-2023 | Fasenra |
| Pulmonx Corporation | $2,820.31 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Noah Medical Corporation | $847.18 | 2024 | Galaxy |
| Glaxosmithkline, LLC. | $773.36 | 2019-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.07 | 2019-2025 | Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $125.01 | 2023 | |
| Pfizer INC. | $121.62 | 2019-2025 | |
| Insmed, INC. | $118.76 | 2024-2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $107.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.35 | 2022-2025 | Glassia |
| Grifols Shared Services North America, INC. | $105.48 | 2023 | Prolastin-C Liquid |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.